Within the ACE Inhibitors Market , hypertension holds the largest share, reflecting the widespread use of ACE inhibitors as first-line therapy for high blood pressure. According to the MRFR report, hypertension is a major risk factor for cardiovascular disease, stroke, and kidney disease. The high prevalence of hypertension globally, estimated to affect over 1 billion people, drives the majority of demand for ACE inhibitors. The segment's dominance is also supported by the availability of generic ACE inhibitors, which are affordable and widely accessible.

While hypertension leads, heart failure and chronic kidney disease (CKD) are the fastest-growing segments. ACE inhibitors are a cornerstone of therapy for heart failure with reduced ejection fraction (HFrEF), improving symptoms, reducing hospitalizations, and prolonging survival. The increasing prevalence of heart failure, driven by an aging population and improved survival from heart attacks, is driving demand for ACE inhibitors. The segment's growth is also supported by the inclusion of ACE inhibitors in major clinical guidelines for heart failure management.

Chronic kidney disease is another significant and growing application. ACE inhibitors are recommended for patients with CKD, particularly those with diabetes, to slow the progression of kidney disease and reduce the risk of end-stage renal disease. The rising prevalence of diabetes and hypertension, the two leading causes of CKD, is driving demand for ACE inhibitors in this segment. The use of ACE inhibitors in CKD is supported by strong clinical evidence demonstrating their renoprotective effects.

Other applications include the management of diabetes (to prevent or delay nephropathy) and the treatment of heart attack (to improve survival). ACE inhibitors are often prescribed to patients who have had a heart attack to reduce the risk of future cardiovascular events. The segment's growth is driven by the increasing incidence of heart attacks and the widespread use of ACE inhibitors in post-MI care.

The growth of the hypertension segment is driven by the high global prevalence of the condition. The growth of the heart failure and CKD segments is driven by the increasing burden of these conditions and the strong clinical evidence supporting the use of ACE inhibitors. As the population ages and the prevalence of these conditions rises, the demand for ACE inhibitors is expected to increase across all applications.